Segall Bryant & Hamill LLC Reduces Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Segall Bryant & Hamill LLC lessened its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,330,314 shares of the biotechnology company's stock after selling 91,882 shares during the quarter. Segall Bryant & Hamill LLC owned approximately 0.64% of BioCryst Pharmaceuticals worth $9,977,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 7.8% during the 4th quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the period. Eversept Partners LP grew its position in shares of BioCryst Pharmaceuticals by 269.9% during the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company's stock valued at $14,892,000 after acquiring an additional 1,444,907 shares during the period. Hillsdale Investment Management Inc. grew its position in shares of BioCryst Pharmaceuticals by 65,213.3% during the 4th quarter. Hillsdale Investment Management Inc. now owns 542,100 shares of the biotechnology company's stock valued at $4,077,000 after acquiring an additional 541,270 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $3,983,000. Finally, Norges Bank acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at about $3,947,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Trading Down 1.0%

Shares of BCRX traded down $0.09 during mid-day trading on Friday, hitting $8.61. 3,104,683 shares of the company's stock were exchanged, compared to its average volume of 3,039,523. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $6.02 and a fifty-two week high of $11.31. The firm has a market capitalization of $1.80 billion, a P/E ratio of -33.12, a P/E/G ratio of 1.41 and a beta of 1.04. The business's 50 day moving average is $9.92 and its two-hundred day moving average is $8.69.

Wall Street Analysts Forecast Growth

BCRX has been the topic of several research analyst reports. Bank of America lifted their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday, July 1st. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 target price on the stock. Barclays raised their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a research note on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, June 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $16.70.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.